Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-03. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Parathyroid hormone regulates serum calcium through its effects on bone, kidney, and the intestine: In bone, PTH enhances the release of calcium from the large reservoir contained in the bones. Bone resorption is the normal destruction of bone by osteoclasts, which are indirectly stimulated by PTH. Stimulation is indirect since osteoclasts do not have a receptor for PTH; rather, PTH binds to osteoblasts, the cells responsible for creating bone. Binding stimulates osteoblasts to increase their expression of RANKL and inhibits their secretion of osteoprotegerin (OPG). Free OPG competitively binds to RANKL as a decoy receptor, preventing RANKL from interacting with RANK, a receptor for RANKL. The binding of RANKL to RANK (facilitated by the decreased amount of OPG available for binding the excess RANKL) stimulates osteoclast precursors, which are of a monocyte lineage, to fuse. The resulting multinucleated cells are osteoclasts, which ultimately mediate bone resorption. Estrogen also regulates this pathway through its effects on PTH. Estrogen suppresses T cell TNF production by regulating T cell differentiation and activity in the bone marrow, thymus, and peripheral lymphoid organs. In the bone marrow, estrogen downregulates the proliferation of hematopoietic stem cells through an IL-7-dependent mechanism. In the kidney, around 250 mmol of calcium ions are filtered into the glomerular filtrate per day. Most of this (245 mmol/d) is reabsorbed from the tubular fluid, leaving about 5 mmol/d to be excreted in the urine.
=== Oral administration === Adequate and well-controlled studies with eflornithine have not been performed regarding pregnancy in humans. Eflornithine should only be used during pregnancy if the potential benefit outweighs the potential risk to the fetus. However, since African trypanosomiasis has a high mortality rate if left untreated, treatment with eflornithine may justify any potential risk to the fetus.
November 10: Todor Zhivkov, the Communist leader of Bulgaria, is removed from office after 35 years in power. November 17–28: The Velvet Revolution brought the end of the authoritarian one-party rule in Czechoslovakia. December 2: End of the Second Malayan Emergency with the Peace Agreement of Hat Yai 1989. December 3: At the end of the Malta Summit, Soviet leader Mikhail Gorbachev and US President George H. W. Bush declare that a long-lasting era of peace has begun. Many observers regard this summit as the official beginning of the end of the Cold War. December 10: The Mongolian Revolution begins when Mongolians held peaceful demonstrations to end the one-party rule in the country. December 14: Democracy is restored in Chile. December 16–25: Rioters during the Romanian Revolution overthrow the Communist government of Nicolae Ceauşescu, executing him and his wife, Elena. Romania was the only Eastern Bloc country to violently overthrow its Communist government or to execute its leaders. December 20: The United States initiates Operation Just Cause. December 24: The First Liberian Civil War begins. December 25: The Romanian Communist Party, the former ruling party of Romania, is dissolved. December 29: Václav Havel becomes President of the now free Czechoslovakia.
Wright Museum of African American History, and several other institutions—by constructing a public space that creates a sense of inclusion and harmony with the rest of the city. Public transportation within the Downtown area has also been a target for private investors, as evidenced by Quicken Loans' investment in Detroit's QLine railcar, which currently runs a 3.3 miles (5.3 km) track along Woodward Avenue. Gilbert's investment within the city is not limited to real estate; he has also assembled a security force that patrols the downtown area and monitors hundreds of security centers attached to buildings operated by his own Rock Ventures. These agents have eyes on almost every corner of downtown Detroit and coordinate public safety and monitor legal infractions in partnership with Wayne State University's private police agency and Detroit's own police force. In addition to these efforts to revitalize Detroit's social atmosphere, Gilbert and Quicken Loans have cultivated a strong and diverse workforce within Detroit by incentivizing employees to live in Midtown and offering subsidies and loans. Through such initiatives, Gilbert has focused on "creating opportunity" for Detroiters and encouraged reinvestment within the city's economy. However, the approach many of these private investors have taken within the downtown area has been criticized. Many have argued that the influx of private capital into Downtown Detroit has resulted in dramatic changes to the social and socio-economic character of the city.
Sources: en.wikipedia.org
== Business model and operations == Seer receives revenue from the sale of products to government, academic, biopharma, and contract research organization (CRO) customers, and by providing proteomics services through its Seer Technology Access Center (STAC) in Redwood City and Bonn, Germany. Seer has approximately 140 employees, including sales and customer support staff in the USA, Europe, and Asia. The company’s headquarters, including its research and development, is located in Redwood City, California, with additional offices in San Diego, California, and a services laboratory in Bonn, Germany. The company generated $14.2 million of revenue in 2024.
=== COVID-19 === The pharmacokinetic boosting property of ritonavir has been successfully repurposed for the treatment of COVID-19. It is co-packaged with nirmatrelvir, a SARS-CoV-2 main protease (3CLpro) inhibitor, under the brand name Paxlovid. In this combination regimen, ritonavir has no direct activity against SARS-CoV-2; rather, it inhibits the CYP3A4-mediated metabolism of nirmatrelvir, enhancing its systemic exposure to levels sufficient to halt viral replication. Clinical trials demonstrated that this combination significantly reduced the risk of hospitalization or death in high-risk patients when administered early (within five days of symptom onset), leading to emergency use authorizations and approvals by agencies such as the US Food and Drug Administration (FDA) and the World Health Organization (WHO).
Androgens and anabolic steroids like testosterone, dihydrotestosterone (DHT), nandrolone, and oxandrolone, which are full agonists of the androgen receptor, produce virilizing or masculinizing effects like increased sebum production and acne, increased body hair growth, scalp hair loss, voice deepening, increased muscle mass, android fat redistribution, skeletal changes like widening of the shoulders and skull/facial changes, and genital growth both in males and females. SARMs, which are tissue-selective mixed or partial agonists of the androgen receptor, are largely uncharacterized in terms of their masculinizing effects, but are likely to produce many of the same effects. SARMs specifically may be expected to retain masculinizing effects like increased muscle mass and bone changes, while possibly having reduced virilizing effects in certain other areas like androgenic skin and hair changes. Anecdotal reports of masculinization with SARMs in women exist in online forums. The United States Food and Drug Administration (FDA) has cautioned that SARMs could have serious adverse effects ranging from risk of heart attack to stroke and liver damage and has warned against their use in bodybuilding products.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.